Sign in

John Metzcar

@jmetzcar.bsky.social
61 followers 125 following 7 posts

I make and use dynamic models to help make decisions and understand biology, cancer, and therapies. Currently at the TMDC @UMNCSE #mathonc #NETs

PostsRepliesMedia
John Metzcar @jmetzcar.bsky.social · 09/03/2026
Great opportunity for graduate students, post docs, and early career non-tenure track researchers to have their work elevated at #SMB2026 and #ECMTB2026!! Thanks to the #MathOnco SMB subgroup for creating this opportunity!! @smbmathbiology.bsky.social @mathonco.bsky.social
171
Reposted by John Metzcar
Neuroendocrine Tumor Research Foundation @netrf.org · 12/02/2026
Congratulations to Mauro Cives, MD, a recipient of a 2025 NETRF Investigator Award for his work with Co-Investigator Anguraj Sadanandam, PhD, to advance immunotherapy for pancreatic neuroendocrine tumors (#PanNETs)! Learn more ➡️ ow.ly/oWTS50YekyL #NeuroendocrineCancer #NETRFGrants
042
Reposted by John Metzcar
Fabian Spill @fabianspill.bsky.social · 10/09/2025
Congrats Margherita on completing her @physicell.bsky.social model investigating the effect of ECM organisation and remodelling and the interplay with chemotaxis on invasion www.biorxiv.org/content/10.1... Great collaboration with @jmetzcar.bsky.social , @mathcancer.bsky.social and Pradeep
biorxiv.org
The role of contact guidance and ECM remodelling in cancer invasion: a computational study
The extracellular matrix (ECM) is a complex network of fibrous proteins and other macro-molecules that provides crucial mechanical and biochemical cues that regulate cancer cell invasion and tumour pr...
233
Reposted by John Metzcar
Neuroendocrine Tumor Research Foundation @netrf.org · 12/08/2025
Be a part of ‪Endocrine Oncology's ‬special collection celebrating the contributions and leadership of women in Neuroendocrine Tumour (NET) research. Original research, reviews and case reports all welcome! 🔗https://eo.bioscientifica.com/page/Women-in-NETs Submit your proposal: eo@bioscientifica.com
022
Reposted by John Metzcar
Paul Macklin @mathcancer.bsky.social · 29/07/2025
Excited for this @cp-cell.bsky.social article co-led by @fertiglab.bsky.social and Genevieve Stein-O'Brien, on creating a plain language "grammar" to easily write simulation models as virtual laboratories for complex systems like cancer. Fully open access and open source! 🧪 #mathonco #mathbio
22914
Reposted by John Metzcar
Waggoner Lab @labwaggoner.bsky.social · 26/07/2025
A plain text modeling language—a cell behavior hypothesis grammar—to easily build virtual cell models and connect them to data, helping scientists to unlock the hidden dynamics of tissues @cellcellpress.bsky.social @mathcancer.bsky.social www.cell.com/cell/fulltex...
0178
Reposted by John Metzcar
Dan Ruderman @danruderman.bsky.social · 25/07/2025
Fantastic work, @mathcancer.bsky.social ! phys.org/news/2025-07...
phys.org
New software simulates cancer cell behavior using genomics and computational models
In the same vein as weather forecast models that predict developing storms, researchers have now developed a method to predict the cell activity in tissues over time. The new software combines genomic...
1164
Reposted by John Metzcar
International Neuroendocrine Cancer Alliance (INCA) @inca-netcancerday.bsky.social · 16/06/2025
Due to early detection of #MultipleEndocrineNeoplasia type 2A (MEN2A), made possible by the genetic test, and the high chance of MTC, surgery to remove the thyroid gland is now done in children who carry the gene. ✅Get informed in 11 languages: incalliance.org/net-info-pac... #LetsTalkAboutNETs
021
Reposted by John Metzcar
Thor Halfdanarson @oncothor.bsky.social · 18/04/2025
Time to rethink our approach to NET grading and use whole slide analysis (WSA) in addition to hotspot analysis (HSA) when assigning tumor grade using Ki-67? It certainly seems so.... @IHC_guy www.modernpathology.org/article/S089...
modernpathology.org
Optimal Approaches to Grading Entero-Pancreatic Neuroendocrine Tumors Using Ki-67 Proliferation Index (Hotspot and Whole Slide Digital Quantitative Analysis)
Grading neuroendocrine tumors using Ki-67 PI is essential for prognostic assessment and therapeutic decision-making. However, the absence of standardized guidelines has led to methodological inconsist...
061
Reposted by John Metzcar
Thor Halfdanarson @oncothor.bsky.social · 18/04/2025
Wishing you had access to new and updated guidelines on MEN1...? Worry not, this team has you covered. www.sciencedirect.com/science/arti...
sciencedirect.com
American Association of Clinical Endocrinology Consensus Statement on Management of Multiple Endocrine Neoplasia Type 1
This document presents the findings of the American Association of Clinical Endocrinology (AACE) on the diagnosis, management, and surveillance of pat…
031
Reposted by John Metzcar
MathOnco @mathonco.bsky.social · 04/04/2025
Machine learning for model parameterization: mathematical-oncology.org/blog/machine... @hamiscalculated.bsky.social @jmetzcar.bsky.social @stolzbernadette.bsky.social #MathOnco #MachineLearning
mathematical-oncology.org
BIRS Recap: Machine learning for model parameterization
mathematical-oncology.org
036
Reposted by John Metzcar
Thor Halfdanarson @oncothor.bsky.social · 28/02/2025
PRRT + PARP inhibitors in advanced NETs? To date, no trials have convincingly shown that PRRT + drug X (whatever that may be) is better than PRRT alone. The addition of PARPi seems to add little early toxicity but larger trials needed to show efficacy. jnm.snmjournals.org/content/earl...
jnm.snmjournals.org
177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial
This phase I trial aimed to assess the feasibility and toxicity of combining the poly(adenosine diphosphate–ribose) polymerase inhibitor olaparib with 177Lu-DOTATATE in patients with somatostatin rece...
052
Reposted by John Metzcar
Adam MacLean @adamlmaclean.bsky.social · 12/02/2025
Thanks to everyone for a fantastic meeting #SACB2025 @cancersysbio.bsky.social (I sure needed an injection of great science in *these times*) @mathcancer.bsky.social closing out the show...
0124
Reposted by John Metzcar
Endocrine Oncology @endocrineoncology.bsky.social · 13/02/2025
Improving #neuroendocrine #tumor treatments with mathematical modeling: lessons from other endocrine cancers By John Metzcar et al. @kelines.bsky.social Read it here 👉 doi.org/10.1530/EO-24-0025
165